Search

Your search keyword '"Vallera, Daniel A."' showing total 539 results

Search Constraints

Start Over You searched for: Author "Vallera, Daniel A." Remove constraint Author: "Vallera, Daniel A."
539 results on '"Vallera, Daniel A."'

Search Results

3. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML

8. Supplementary Materials from Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR

9. Data from Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR

10. Methods and figures from ImmunoPET, [64Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model

11. Data from ImmunoPET, [64Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model

12. Supplemental Table 2 from IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

13. Supplemental Figure Legends from IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

14. Supplementary Figure 2 from IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

15. Supplementary Figure 1 from IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

16. Supplemental Table 1 from IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

17. A tri-specific killer engager against mesothelin targets NK cells towards lung cancer

19. 1202 Tri-specific killer engagers target natural killer cells towards mesothelioma

21. Immunotherapeutic Development of a Tri-Specific NK Cell Engager Recognizing BCMA.

25. Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia

28. 444 GTB-3550 tri-specific killer engager TriKE™ drives NK cells expansion and cytotoxicity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients

37. Contributors

43. Potent Cytolytic Activity and Specific IL15 Delivery in a 2(nd) Generation Trispecific Killer Engager

48. GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

49. 470 Targeting Pan-Tumor Associated Antigen B7H3 via Combination of Tri-specific Killer Engager and Off-the-shelf NK Cell Therapy Enhances Specificity and Function Against a Broad Range of Solid Tumors

Catalog

Books, media, physical & digital resources